Affinity DataEC50: 5.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 5.70E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 4.70E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.70E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 4.50E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 5.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.90E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 7.90E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.40E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 4.20E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 9.30E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 2.10E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.20E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.50E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.40E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 5.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.30E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
![](/img/powered_by_small.gif)